This blog is a collection of my favorite new treatments for liver cancer currently available through clinical trials. The start of each post contains a brief description of the approach, reasons I included it and a link to the trial website.

JX-594 Update: Improved Survival for Patients with Advanced Hepatocellular Carcinoma

In this phase II trial of patients with advanced, previously treated hepatocellular carcinoma (HCC),  52% of patients exhibited disease stabilization. The median overall survival was  13.8 mths with 25% of patients survived 32 mths (to date)…. [Learn More…]

JX-594: A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma

JX-594 is a targeted and granulocyte-macrophage colony stimulating factor (GM-CSF) expressing oncolytic poxvirus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. In this trial,… [Learn More…]